Antileukemia Activity of Human Natural Killer Cell-Derived Nanomagic Bullets against Acute Myeloid Leukemia (AML).

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Extracellular Vesicles in Acute Myeloid Leukemia: Opportunities and Obstacles for Therapeutic Advancement.Journal of biochemical and molecular toxicology · 2026
   Review
2. Extracellular vesicles in the immune regulation of hematological malignancies: mechanisms, prognostic significance, and therapeutic opportunities.Frontiers in cell and developmental biology · 2026
   Review
3. NK-derived exosomes in anti-tumor strategies.Medical oncology (Northwood, London, England) · 2025
   Review
4. The Effects of Released Exosomes from NK-92 Cells with IL15 on the Apoptosis of HL-60 Cell Line.International journal of hematology-oncology and stem cell research · 2025
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

5 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as